US 12,442,818 B2
Autoantibodies as biomarker of paraneoplastic encephalitis associated with testicular cancer
Joseph L. DeRisi, San Francisco, CA (US); Michael R. Wilson, Oakland, CA (US); Caleigh Mandel-Brehm, Oakland, CA (US); Brian O'Donovan, Oakland, CA (US); Sean J. Pittock, Rochester, MN (US); Divyanshu Dubey, Rochester, MN (US); Thomas J. Kryzer, Mantorville, MN (US); Vanda A. Lennon, Rochester, MN (US); and Andrew McKeon, Rochester, MN (US)
Assigned to CZ Biohub SF, LLC; The Regents of the University of California; and Mayo Foundation for Medical Education and Research
Appl. No. 17/439,359
Filed by CZ Biohub SF, LLC, San Francisco, CA (US); The Regents of the University of California, Oakland, CA (US); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
PCT Filed Mar. 13, 2020, PCT No. PCT/US2020/022592
§ 371(c)(1), (2) Date Sep. 14, 2021,
PCT Pub. No. WO2020/190700, PCT Pub. Date Sep. 24, 2020.
Claims priority of provisional application 62/819,379, filed on Mar. 15, 2019.
Prior Publication US 2022/0196662 A1, Jun. 23, 2022
Int. Cl. G01N 33/574 (2006.01); A61K 38/45 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); G01N 33/564 (2006.01)
CPC G01N 33/57407 (2013.01) [A61K 38/45 (2013.01); A61K 39/395 (2013.01); A61P 35/00 (2018.01); G01N 33/564 (2013.01); G01N 2800/28 (2013.01)] 26 Claims
 
1. A method of detecting the presence of a Kelch-like protein 11 (KLHL11) autoantibody in a biological sample from a male subject presenting with encephalitis, comprising the steps of:
(a) contacting the biological sample with a KLHL11 polypeptide or antigenic fragment thereof, the polypeptide or fragment thereof having at least 95% identity to one or more sequences of SEQ ID NOs: 1-30; and
(b) detecting the presence of binding of the KLHL11 polypeptide or antigenic fragment thereof to the KLHL11 autoantibody in the biological sample.